IXICO shares rise 4% on stronger-than-expected revenue growth

IXICO PLC shares climbed 4% after the neuroscience data firm reported a 13% increase in annual revenue to £6.5 million, exceeding market expectations, driven by new contract wins and expansion in neurodegenerative disease research. The company nearly doubled its year-end cash balance to £3.5 million and anticipates an EBITDA loss no greater than £1.6 million, an improvement from the previous year, despite a slight decline in its order book to £13.8 million. This performance, reflecting strategic investments, suggests a trajectory towards sustainable growth.

Analysis

IXICO PLC reported a 13% year-over-year increase in annual revenue to £6.5 million, surpassing market expectations, which led to a 4% rise in its share price to 13p. This growth was primarily driven by new contract acquisitions, extensions of existing agreements, and strategic expansion within the neurodegenerative disease research sector. The company's use of AI-based imaging analytics underpins its competitive positioning in drug development for neurological disorders.

The company significantly strengthened its financial position, nearly doubling its year-end cash balance to £3.5 million following a £3.7 million capital raise. Despite a slight reduction in the overall order book to £13.8 million from £15.3 million, strong second-half momentum saw £4.2 million in new and extended contracts signed. IXICO anticipates an improved EBITDA loss, projected to be no greater than £1.6 million, which is better than forecasts and narrower than the prior year's £1.7 million loss.

Chief executive Bram Goorden highlighted these results as an early indication of successful strategic investments, suggesting a trajectory towards sustainable growth. The firm has already secured an additional £0.9 million in new work since the start of the current financial year, reinforcing its positive momentum. Audited results, expected in December, will provide further detailed confirmation of these preliminary figures.

Key Decisions for Investors

• Monitor the upcoming audited results in December for confirmation of the preliminary positive financial indicators and any further guidance on future growth drivers.
• Evaluate the sustainability of revenue growth, particularly the impact of new contract wins and expansion into neurodegenerative disease research, in light of the slight decline in the overall order book.
• Assess the company's trajectory towards profitability, focusing on the narrowing EBITDA loss and the effective deployment of capital raised to achieve sustainable growth.